Oculis announces second Phase 3 OPTIMIZE-2 trial for once-daily
cataract surgery

Oculis announces second Phase 3 OPTIMIZE-2 trial for once-daily

OCS-01 is the first once-daily topical, preservative-free corticosteroid. I